On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for the rights to future royalties on rusfertide, an experimental therapy for a uncommon blood disorder called polycythemia vera. It is Royalty Pharma’s second collaboration with Zealand, and it arrives just as rusfertide awaits a choice from the FDA. For a company that makes its residing shopping for items of other corporations’ medication, the timing says a lot about how it weighs risk against reward before a regulatory verdict even lands.
Buying Conviction Ahead Of A Verdict
Royalty Pharma’s business relies upon on choosing the proper second to buy into a drug’s future, and this deal suits that sample. Under the settlement, $50 million adjustments fingers at closing and the remaining $50 million arrives on the first anniversary, in exchange for a 1% royalty on rusfertide’s world gross sales plus any regulatory and business milestones. Rusfertide, a once-weekly self-injected therapy that mimics the hormone hepcidin to control iron ranges in polycythemia vera sufferers, already has an FDA objective date set for the third quarter of 2026, with Takeda lined up to deal with commercialization worldwide. That is a near-term catalyst most royalty purchases do not carry.
The broader portfolio backs up the confidence. Royalty Receipts grew 14% to $768 million in the second quarter of 2026, lifted by Tremfya, Voranigo, Imdelltra and Evrysdi, and the company raised its full-year 2026 steerage for Portfolio Receipts to a vary of $3.4 billion to $3.5 billion, the second increase this 12 months. Capital deployment has already topped $1 billion in 2026, including a July 2026 royalty buy tied to AstraZeneca’s cliramitug, pushing the development-stage pipeline to 19 potential therapies. Even after repaying a $380 million time period loan in July 2026, Royalty Pharma still paid a quarterly dividend of $0.235 per share and purchased back $45 million of stock in the second quarter alone.
When Royalties Run Dry
Not every royalty ages properly, and Royalty Pharma’s own numbers show it. Promacta royalties fell 75% in the second quarter of 2026 to just $8 million as US generic competitors took maintain, and Imbruvica funds slipped 16% to $36 million, a reminder that patent cliffs finally catch up to even the steadiest money flows. That same risk sits beneath every new deal the company indicators, including the one with Zealand.
The rusfertide settlement carries its own strings. Royalty Pharma’s 1% royalty stops scaling once world gross sales cross $1.5 billion, at which level Zealand retains a 0.25% cut and Royalty Pharma only 0.75%, so the largest business outcomes get cut up rather than totally captured. And rusfertide still has not cleared the FDA. The company’s objective date only falls in the third quarter of 2026, which means the second $50 million fee is dedicated before regulators end their review. Layer that onto a stability sheet carrying $9.2 billion in whole debt principal against $812 million of money as of June 30, 2026, and it becomes clear this is a company funding new bets with borrowed as properly as earned capital, even while working through roughly $350 million to $360 million in expected curiosity funds for the 12 months.